Stockholm, Sweden (Press Release) – Oncopeptides AB (Nasdaq Stockholm: ONCO) to­day an­nounced that the US pat­ent and trademark office has issued a notice that they in­tend to grant addi­tional pat­ents to Oncopeptides AB in the US. Oncopeptides has pre­vi­ously re­ceived the corresponding pat­ent pro­tec­tion both in Japan and Europe.

These pat­ents (application numbers 14/438473 and 15/225323) pro­tect, inter alia, the freeze-dried for­mu­la­tion. The pat­ent pro­tec­tion extends to 2033. The freeze-dried preparation with melflufen is in­tended to be mar­keted at a future ap­­prov­al.

"We have now approved for­mu­la­tion pat­ents in all major key mar­kets for melflufen. This fur­ther in­­creases the pro­tec­tion of melflufen in addi­tion to the composition of matter pat­ent and orphan drug mar­ket exclusivity. The for­mu­la­tion pat­ent has a sig­nif­i­cant stra­te­gic value since the preparation of melflufen to a freeze-dried powder is nec­es­sary in the treat­ment of patients as it is the only stable for­mu­la­tion for melflufen. This is a foundation for the future poten­tial com­mer­cial value of melflufen in these key mar­kets", commented Jakob Lindberg, CEO of Oncopeptides.

About Oncopeptides

Oncopeptides is a pharma­ceu­tical com­pany devel­op­ing drugs for the treat­ment of cancer. The com­pany is focusing on the devel­op­ment of the lead prod­uct can­di­date melflufen, a novel peptide con­ju­gated al­kyl­ator, belonging to a new class of drugs called Peptidase Enhanced Compounds (PEnC). Melflufen is in devel­op­ment as a new treat­ment for the hema­to­logical cancer mul­ti­ple myeloma and is cur­rently being tested in a global pivotal Phase 3 trial and in three addi­tional sup­porting clin­i­cal trials. Oncopeptides' headquarters is located in Stockholm, Sweden and the com­pany is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.

More in­for­ma­tion is avail­able on www.oncopeptides.com.

Source: Oncopeptides.